NT-proBNP in left and right heart disease: a critical tool for better patient outcomes
Date: Thursday, May 29, 2025
Time: 2:00 PM ET / 1:00 PM CT / 11:00 AM PT
Duration: 1 Hour
Already registered? Click here to log in.
Summary
Natriuretic peptides, including BNP and NT-proBNP, are widely recognized as essential biomarkers for diagnosing and managing heart failure. However, their clinical utility extends far beyond traditional heart failure settings. Secreted by cardiomyocytes in response to myocardial stretch, these peptides offer valuable insight into a range of cardiopulmonary and metabolic conditions. This webinar will explore the expanding role of BNP and NT-proBNP in both outpatient and inpatient care, including their application in pulmonary arterial hypertension (PAH) and acute pulmonary embolism (PE).
Learning Objectives:
- Describe how natriuretic peptides contribute to risk stratification, treatment decisions, and disease monitoring.
- Illustrate how to interpret elevated values in different clinical contexts, including stable outpatient management of pulmonary arterial hypertension (PAH) and acute triage decisions in the emergency department for acute pulmonary embolism (PE).
- Discuss current recommendations from recent global clinical guidelines and symposiums.
- Participants will learn how treatments, particularly the use of Entresto, influence NT-proBNP levels and how these changes can guide the optimization of treatment to reduce hospitalization and mortality rates in patients with heart failure.
Speakers
James Januzzi, MD
Adolph Hutter Professor of Medicine; Chief Scientific Officer and C. Michael Gibson Chair; Staff Cardiologist
Harvard Medical School; Baim Institute for Clinical Research; Massachusetts General Hospital
Dr. James Januzzi is the Adolph Hutter Professor of Medicine at Harvard Medical School, Staff Cardiologist at the Massachusetts General Hospital, and serves as the Chief Scientific Officer and C. Michael Gibson Chair at the Baim Institute for Clinical Research. He is a clinician, trialist, and educator. His research work largely focuses on optimizing diagnostics and therapeutics for heart disease. His work with the natriuretic peptides has established international standards for their use in research and clinical applications, and he has helped in the development programs of numerous therapeutics for cardio-kidney-metabolic diseases. As of March of 2025, he has more than 900 publications and greater than 135,000 citations.
Ioana Preston, MD
Director, Pulmonary Hypertension Center; Pulmonologist, Department of Pulmonary and Critical Care Medicine
Lahey Hospital and Medical Center
Dr. Ioana Preston is the Director of the Pulmonary Hypertension Center and a pulmonologist in the Department of Pulmonary and Critical Care Medicine at Lahey Hospital and Medical Center in Burlington, MA. She has expertise in clinical pulmonary hypertension, as well as in preclinical, translational and clinical research. She has participated in numerous clinical trials that led to the approval of therapies in pulmonary hypertension. She is a co-author on more than 80 peer reviewed papers on pulmonary hypertension and was the Chair of the Task Force on “Pulmonary hypertension management in special conditions” at the latest 7th World Symposium for Pulmonary Hypertension 2024. She is the former chair of the Pulmonary Vascular Disease network and a current member of the planning committee of the International Heart and Lung Transplant Society.
